HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Shift Under Biden Administration Begins With Chairman Simons, Senior Staff Resigning

Executive Summary

While expected following start of Biden administration, Simon’s resignation is “somewhat of a surprise” considering it will change the balance of power to the Democrats ahead of when his term would have been ended, says advertising law attorney Ivan Wasserman.

You may also be interested in...

Final Rule To Enforce FTC's ‘Made In USA’ Policy Reveals Commission's Split On Limits To Authority

FTC finalizes “Made in USA” rule codifying longstanding policy that wasn’t enforced. The rule imposes fines up to $43,280 per violation, but Commissioner Christine Wilson says rule is another example of commission exceeding its authority.

FTC Nominee Khan Is Likely To Face Close Senate Vote; Biden Still Has One More Seat To Fill

Columbia’s Khan is known for her critical views of tech industry, which observers expect will transfer to pharma; another possible nominee for the other remaining spot, DC attorney general Karl Racine, is also focused on the tech space. Acting Chair Rebecca Kelly Slaughter’s pharma interest likely means the issue won’t recede from the FTC’s agenda.

Biden Nominates Anti-Trust Expert Khan To FTC

President Biden nominates Lina Khan for one of two FTC commissioner seats he will fill. Khan currently is a Columbia Law associate professor, teaching and writing about antitrust law, infrastructure industries law and the antimonopoly tradition.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts